产品介绍：
产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
ICI 192605 is a potent thromboxane A2 receptor antagonist. It inhibits platelet aggregation and can reverse the effects of vasoconstrictors such as TXA2 or PGD2. ICI 192605 can reverse vasoconstriction induced by inhibition of NO production by L-NEMA, which leads to an increase in TXA2 release.
特点和优势
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
基本信息
| 经验(实验)分子式 | C22H23ClO5 |
| 分子量 | 402.87 |
| MDL编号 | MFCD00673936 |
| PubChem化学物质编号 | 329815367 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | white to tan |
| 溶解性 | DMSO: ≥20 mg/mL |
| 创始人 | AstraZeneca |
| 储存温度 | −20℃ |
| SMILES string | OC(=O)CC\C=C/C[C@H]1CO[C@H](O[C@H]1c2ccccc2O)c3ccccc3Cl |
| InChI | 1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1 |
| InChI key | WHUIENZXNGAHQI-YGPRPMEGSA-N |
安全信息
| 象形图 |   |
| 警示用语： | Warning |
| 危险声明 | H302 - H410 |
| 预防措施声明 | P273 - P501 |
| 危险分类 | Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 |
| 储存分类代码 | 11 - Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
